Medicago Shut Down: COVID-19 Vaccine Competition Among Reasons
$364m Impairment Loss For Mitsubishi
While the close-down schedule for the Canadian vaccine technology specialist is still unclear, all ongoing R&D projects at the firm will be terminated, Japanese parent group tells Scrip.
